Single-dose Pharmacokinetics and Relative Bioavailability of an Oral Suspension and Two Tablet Formulations of BIA 2-093

Inclusion Criteria: * Male or female subjects aged between 18 and 45 years, inclusive. * Subjects of body mass index (BMI) between 19 and 28 kg/m2, inclusive. * Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs and 12-lead ECG at screening. * Subjects who had clinical laboratory tests clinically acceptable at screening. * Subjects who were negative for HBsAg, anti-HCV Ab and HIV-1 and HIV-2 Ab tests at screening. * Subjects who were negative for alcohol and drugs of abuse at screening. * Subjects who were non-smokers or who smoke less than 10 cigarettes or equivalent per day. * Subjects who were able and willing to give written informed consent. * (If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: doublebarrier, intra-uterine device or abstinence. * (If female) She had a negative pregnancy test at screening and admission to each study period. Exclusion Criteria: * Subjects who do not conform to the above inclusion criteria, or * Subjects who have a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders. * Subjects who have a clinically relevant surgical history. * Subjects who have a clinically relevant family history. * Subjects who have a history of relevant atopy. * Subjects who have a history of any drug hypersensitivity. * Subjects who have a history of alcoholism or drug abuse. * Subjects who consume more than 14 units of alcohol a week. * Subjects who have a significant infection or known inflammatory process on screening and/or first admission. * Subjects who have acute gastrointestinal symptoms at the time of screening and/or first admission (e.g., nausea, vomiting, diarrhoea, heartburn). * Subjects who have used medicines within 2 weeks of admission to first period. * Subjects who have participated in any clinical trial within 3 months prior to screening. * Subjects who have previously received BIA 2-093. * Subjects who have donated and/or received any blood or blood products within the previous 3 months prior to screening. * Subjects who are vegetarians, vegans and/or have medical dietary restrictions. * Subjects who cannot communicate reliably with the investigation team. * Subjects who are unlikely to co-operate with the requirements of the study. * Subjects who are unwilling or unable to give written informed consent. * (If female) She is pregnant or breast-feeding. * (If female) She is of childbearing potential and she does not use an approved effective contraceptive method or she uses oral contraceptives.